Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide

Cardiovascular Research
A BrilJ F Faivre

Abstract

The effects of BRL-32872, azimilide and a selective blocker of the delayed rectifier potassium current, E-4031, were measured at two different basic cycle lengths (BCL), 300 and 1000 ms. Calcium channel antagonists of sarcolemmal (verapamil and nitrendipine) and sarcoplasmic reticulum (ryanodine) membranes were used to investigate whether the inhibition of the calcium current or the calcium release from the sarcoplasmic reticulum could alter the reverse-rate dependence of E-4031 on action potential duration (APD). Guinea pig isolated papillary muscles were superfused with a Tyrode solution maintained at 37 degrees C and stimulated at a BCL of 300 or 1000 ms. The standard microelectrode technique was used to record action potential parameters and to study the effects of azimilide, BRL-32872 and E-4031. E-4031 was superfused at increasing concentrations (0.01, 0.03, 0.1 and 0.3 microM) in the absence or in the presence of verapamil (0.3 microM), nitrendipine (0.03 microM) or ryanodine (0.1 microM). BRL-32872 and azimilide induced a self-limited concentration-dependent increase in APD. The effect of BRL-32872 was not dependent on the stimulation frequency whereas the effect of azimilide was significantly reduced at the shorter BCL...Continue Reading

Citations

Jun 12, 2003·European Journal of Pharmacology·János TakácsJulius Gy Papp
Aug 23, 2002·Pharmacology & Therapeutics·Alan Wickenden
Apr 22, 1999·General Pharmacology·T BányászP P Nánási
Oct 7, 2000·Clinical and Experimental Pharmacology & Physiology·H J Witchel, J C Hancox
Jun 27, 2009·Cardiovascular Research·Tamás BányászPéter P Nánási
Jul 12, 2008·Pharmacology & Therapeutics·Jules C HancoxYi Hong Zhang
Jan 19, 2011·Fundamental & Clinical Pharmacology·Paolo Emilio PudduJoffrey Ducroq
May 18, 2010·Basic & Clinical Pharmacology & Toxicology·Martin Fink, Denis Noble
Apr 23, 2004·Expert Opinion on Investigational Drugs·Sheila A Doggrell, Jules C Hancox
Feb 28, 2003·Expert Opinion on Investigational Drugs·Jan Nemec, Win-Kuang Shen
Mar 24, 2000·Drugs·D Clemett, A Markham
Jan 25, 2003·Journal of Clinical Psychopharmacology·Harry J WitchelDavid J Nutt
Aug 15, 2002·Cardiovascular Drug Reviews·Christoph A KarleJohann Kiehn
Dec 31, 2021·Archiv der Pharmazie·Grigory V Mokrov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.